Wellness tracking app developer Biobeats has been bought after raising a total of $6.3m in funding from investors including Axa, Samsung and Cantora.

Long-term investors Johnson & Johnson Innovation, JJDC and Pfizer Ventures took part in a round that boosted the radiotherapy developer's overall funding to $264m.

The radiotherapy developer, which is exploiting UChicago research, has now raised $264m in funding overall.

Huma has bought Surrey-founded wellness tracking app developer Biobeats to increase the number of digital biomarkers that underpin its services.

Emergent BioSolutions-backed Avectas has added $20m to its coffers to help drug developers create cancer treatments.

OSF Ventures invested $2m to bring the lung-imaging technology provider's latest round, which already included UnityPoint Health, to $13m.

The aeests of Intel Capital and Fitbit-backed glucose monitor developer have been acquired by diabetes-focused peer One Drop.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Disease diagnostics software provider Perspectum secured the return of Oxford and OSI to take its funding total to at least $41m.

The newly rebranded Blue Venture Fund co-led the round, which will support the commercialisation of Perspectum’s liver disease diganostics software.